Edgar Lomax Co. VA Sells 29,960 Shares of Amgen Inc. $AMGN

Edgar Lomax Co. VA decreased its position in Amgen Inc. (NASDAQ:AMGN) by 23.0% during the 3rd quarter, Holdings Channel reports. The firm owned 100,310 shares of the medical research company’s stock after selling 29,960 shares during the quarter. Amgen makes up 2.2% of Edgar Lomax Co. VA’s investment portfolio, making the stock its 17th biggest holding. Edgar Lomax Co. VA’s holdings in Amgen were worth $28,307,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Schnieders Capital Management LLC. boosted its holdings in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Csenge Advisory Group increased its position in Amgen by 0.6% in the second quarter. Csenge Advisory Group now owns 6,383 shares of the medical research company’s stock worth $1,839,000 after purchasing an additional 40 shares during the period. Finally, Asahi Life Asset Management CO. LTD. raised its holdings in Amgen by 4.9% during the 2nd quarter. Asahi Life Asset Management CO. LTD. now owns 9,312 shares of the medical research company’s stock worth $2,600,000 after purchasing an additional 434 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald raised their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Truist Financial raised their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Rothschild & Co Redburn upped their target price on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $354.17.

Amgen Price Performance

Shares of AMGN stock opened at $367.60 on Friday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The firm has a market capitalization of $198.16 billion, a price-to-earnings ratio of 25.83, a price-to-earnings-growth ratio of 3.76 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a fifty day moving average of $352.53 and a 200-day moving average of $321.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter last year, the business posted $5.31 EPS. The firm’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board approved a $2.52 quarterly dividend, payable June 5, 2026, supporting income investors and signaling cash-flow confidence. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Positive Sentiment: Amgen launched a new Phase 3 subcutaneous trial to expand its blinatumomab franchise — a constructive pipeline development that could add long-term value if successful. Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference on March 11; management comments (CFO and SVP of rare disease) could offer incremental guidance or pipeline color. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Coverage pieces examine post-earnings momentum and valuation (why AMGN has risen ~24% over the past year); useful for context but not single-driver news. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Neutral Sentiment: Reported short-interest data in early March appears erroneous (0 shares / NaN change); treat as noise until reliable data is posted. (No link available)
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals tying OX40 modulation to potential malignancies — this removes a late‑stage asset and raises near-term pipeline risk and uncertainty around R&D priorities. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: An analyst downgrade recommended waiting for a better entry point (rating cut / hold), which can amplify selling pressure after the pipeline news. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.